DDX17

Across TCGA pan-cancer cohorts, DDX17 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of DDX17’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where DDX17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DDX17 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

LIHC, HNSC, and CHOL are the cancer types where DDX17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DDX17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	II,III,IV	+0.799	<.001	9	view →
HNSC	All	All	+0.366	.005	6	view →
CHOL	Male	All	+2.024	<.001	5	view →
KICH	All	All	−0.795	<.001	5	view →
THCA	Female	All	−0.593	<.001	5	view →
BRCA	Female	All	−0.407	<.001	4	view →
UCEC	All	All	−0.596	<.001	2	view →
KIRP	Male	All	−0.476	.017	2	view →
LUAD	All	II,III,IV	−0.361	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

DDX17–LIHC

Open the LIHC breakdown →